XML 16 R5.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024 0      
Beginning balance at Dec. 31, 2024 $ 0      
Ending balance (in shares) at Jun. 30, 2025 0      
Ending balance at Jun. 30, 2025 $ 0      
Beginning balance (in shares) at Dec. 31, 2024   4,447,000    
Beginning balance at Dec. 31, 2024 (46,794) $ 0 $ 101,657 $ (148,451)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (13,523)     (13,523)
Issuance of 2025 Blue Owl Warrants in connection with the Loan Agreement 3,934   3,934  
Vesting of restricted stock units (in shares)   75,000    
Repurchases of restricted stock for payroll tax withholding (in shares)   (36,000)    
Repurchases of restricted stock for payroll tax withholding (361)   (361)  
Stock-based compensation expense 1,930   1,930  
Issuance of shares due to litigation settlement (in shares)   84,000    
Issuance of shares due to litigation settlement 752   752  
Ending balance (in shares) at Jun. 30, 2025   4,570,000    
Ending balance at Jun. 30, 2025 $ (54,062) $ 0 107,912 (161,974)
Beginning balance (in shares) at Mar. 31, 2025 0      
Beginning balance at Mar. 31, 2025 $ 0      
Ending balance (in shares) at Jun. 30, 2025 0      
Ending balance at Jun. 30, 2025 $ 0      
Beginning balance (in shares) at Mar. 31, 2025   4,484,000    
Beginning balance at Mar. 31, 2025 (51,687) $ 0 102,452 (154,139)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (7,835)     (7,835)
Issuance of 2025 Blue Owl Warrants in connection with the Loan Agreement 3,934   3,934  
Vesting of restricted stock units (in shares)   13,000    
Repurchases of restricted stock for payroll tax withholding (in shares)   (11,000)    
Repurchases of restricted stock for payroll tax withholding (90)   (90)  
Stock-based compensation expense 864   864  
Issuance of shares due to litigation settlement (in shares)   84,000    
Issuance of shares due to litigation settlement 752   752  
Ending balance (in shares) at Jun. 30, 2025   4,570,000    
Ending balance at Jun. 30, 2025 $ (54,062) $ 0 107,912 (161,974)
Beginning balance (in shares) at Dec. 31, 2025 65,000,000      
Beginning balance at Dec. 31, 2025 $ 27,909      
Ending balance (in shares) at Jun. 30, 2026 65,000,000      
Ending balance at Jun. 30, 2026 $ 27,909      
Beginning balance (in shares) at Dec. 31, 2025 4,750,258 4,750,000    
Beginning balance at Dec. 31, 2025 $ (38,083) $ 0 109,003 (147,086)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 1,298     1,298
Vesting of restricted stock units (in shares)   58,000    
Repurchases of restricted stock for payroll tax withholding (in shares)   (16,000)    
Repurchases of restricted stock for payroll tax withholding (108)   (108)  
Stock-based compensation expense $ 858   858  
Ending balance (in shares) at Jun. 30, 2026 4,792,405 4,792,000    
Ending balance at Jun. 30, 2026 $ (36,035) $ 0 109,753 (145,788)
Beginning balance (in shares) at Mar. 31, 2026 65,000,000      
Beginning balance at Mar. 31, 2026 $ 27,909      
Ending balance (in shares) at Jun. 30, 2026 65,000,000      
Ending balance at Jun. 30, 2026 $ 27,909      
Beginning balance (in shares) at Mar. 31, 2026   4,765,000    
Beginning balance at Mar. 31, 2026 (31,927) $ 0 109,473 (141,400)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (4,388)     (4,388)
Vesting of restricted stock units (in shares)   32,000    
Repurchases of restricted stock for payroll tax withholding (in shares)   (5,000)    
Repurchases of restricted stock for payroll tax withholding (32)   (32)  
Stock-based compensation expense $ 312   312  
Ending balance (in shares) at Jun. 30, 2026 4,792,405 4,792,000    
Ending balance at Jun. 30, 2026 $ (36,035) $ 0 $ 109,753 $ (145,788)